Prospective, Open-label, Randomised Controlled Trial on Efficacy and Tolerability of PegIFN-alpha 2a + Serum Level-adapted RBV vs. PegIFN-alpha 2a + Weight-based RBV in Treatment-naive Patients With Chronic Hepatitis C Genotype 1.
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2015
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 10 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jul 2009 New trial record